10-Q: Akari Narrows Loss Amid Going Concern Doubts

Akari Therapeutics reported a significantly reduced net loss in the first half of 2025, driven by strategic pipeline prioritization, but continues to face substantial doubt about its ability to continue as a going concern without further financing.

Summary

• Net loss for the six months ended June 30, 2025, significantly decreased to $5.6 million from $13.1 million in the same period of 2024.
• Loss from operations for the six months ended June 30, 2025, decreased by 51% to $6.6 million from $13.4 million in 2024.
• Research and development expenses decreased by 74% to $1.48 million for the six months ended June 30, 2025, compared to $5.593 million in 2024, due to the suspension of legacy programs.
• Cash balance as of June 30, 2025, was $2.711 million, which is not sufficient to fund operations for the next 12 months.
• The company completed a March 2025 Private Placement, raising approximately $5.6 million in net proceeds, including $1.0 million from the cancellation of notes held by the Chairman.
• In August 2025, the company entered into agreements for a $3 million private placement of unsecured promissory notes with a 20% original issuance discount, with an aggregate principal amount of $3.8 million, expected to close in August and September 2025.
• The expiration date of Series A Warrants issued in March 2025 will be extended from 2026 to 2030 for certain August 2025 Note Investors.
• The company settled a lawsuit with Sabby Volatility Warrant Master Fund Ltd. by issuing 272,450 ADSs (544,900,000 ordinary shares) on June 13, 2025.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, have not yet been remediated.

Sentiment

Score: 4

Explanation: While the company significantly reduced its net loss and operating loss, and successfully raised capital, the persistent 'going concern' doubt, low cash balance, and reliance on continuous dilutive financing rounds (including high discount notes) indicate significant financial instability and high risk. The strategic pivot is positive, but its success is long-term and uncertain.

Positives

• Significant reduction in net loss for the six months ended June 30, 2025, to $5.6 million from $13.1 million in the prior year.
• Loss from operations decreased by 51% to $6.6 million for the six months ended June 30, 2025, compared to $13.4 million in the same period of 2024.
• Research and development expenses decreased substantially by 74% to $1.48 million for the six months ended June 30, 2025, reflecting successful cost reduction from pipeline prioritization.
• Achieved a $1.2 million gain on settlement of current liabilities during the six months ended June 30, 2025.
• Successfully completed a March 2025 Private Placement, raising approximately $5.6 million in net proceeds.
• Secured additional funding through the August 2025 Notes Offering for an aggregate purchase price of $3 million, extending the cash runway into October 2025.
• Successfully settled a lawsuit with Sabby Volatility Warrant Master Fund Ltd., resolving a legal proceeding.
• Strategic shift to focus on the Antibody-Drug Conjugate (ADC) platform, particularly AKTX-101, which is believed to have potential for improved efficacy and safety in cancer treatment.

Negatives

• Accumulated deficit increased to $252.852 million as of June 30, 2025, from $247.252 million at December 31, 2024.
• Cash balance of $2.711 million as of June 30, 2025, is insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The company continues to incur substantial losses and negative cash flows from operations.
• Legacy programs (nomacopan HSCT-TMA and PAS-nomacopan) have been suspended from internal development, requiring external partners for future advancement.
• The PHP-303 program also requires external partners for further development, indicating a lack of internal resources or strategic priority.
• Material weaknesses in internal control over financial reporting identified as of December 31, 2024, have not yet been remediated as of June 30, 2025.
• The August 2025 Notes Offering includes a 20% original issuance discount, indicating a high cost of capital.
• The August 2025 Notes Offering includes a 5% advisory fee to Paulson Investment Company on gross cash proceeds, further increasing capital raising costs.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to incurred losses and insufficient cash to fund operations for the next 12 months.
• Need for substantial additional financing through equity, debt, or collaborations, which may not be available on acceptable terms or at all.
• Potential for significant dilution to existing shareholders if additional funds are raised through equity or convertible debt.
• Incurrence of indebtedness could lead to increased fixed obligations and restrictive covenants.
• Uncertainty of pre-clinical research outcomes and successful completion of research and development efforts for product candidates.
• Risks associated with clinical trials of products, including timing, enrollment, and results.
• Dependence on third-party collaborators for research and development operations and potential external licensing partners for legacy programs.
• Uncertainty of obtaining marketing authorization for products.
• Risks associated with protection of intellectual property.
• Competition with larger, better-capitalized companies in the biotechnology industry.
• Material weaknesses in internal control over financial reporting, which could adversely affect the ability to record, process, summarize, and report financial information.
• Potential for delays, reduction in scope, or elimination of research, development, or commercialization plans if sufficient funds are not available.
• Risk of being required to relinquish rights to certain potential products or pursue a company sale on unfavorable terms if funding is insufficient.

Future Outlook

The company anticipates incurring additional losses and negative cash flows for the foreseeable future, with current cash sufficient only into October 2025. Substantial additional financing will be needed to fund operations, potentially through equity or debt offerings, or strategic collaborations. The company expects to continue investing in ADC-related discovery and pre-clinical development activities, while seeking external partners for its legacy nomacopan and PHP-303 programs.

Management Comments

• We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
• We aim to establish AKTX-101 as a potential best-in-class Trop2-targeting ADC for the treatment of a variety of solid tumors.
• We have suspended further internal development of our legacy programs, nomacopan and PAS-nomacopan, and intend to seek strategic partners to advance their development externally.
• For our PHP-303 program... we also intend to seek strategic partners to further its development externally.
• As of the date of this report, our existing cash, together with committed funds from the August 2025 Financing, is sufficient to fund our operations into October 2025.
• While we have additional funding activities in progress to fund our operations, we will need to raise additional capital to continue to fund our operations and service our obligations in the future.
• If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.

Industry Context

Akari Therapeutics is pivoting its strategy to focus on the highly competitive and rapidly evolving field of Antibody-Drug Conjugates (ADCs) for cancer treatment. This shift aligns with a broader industry trend towards targeted therapies and next-generation oncology solutions. By focusing on novel payloads like PH1, Akari aims to differentiate itself from existing ADC therapies that primarily rely on a limited set of payload classes (microtubule inhibitors or DNA-damaging agents). The company's strategy to seek external partners for its legacy programs (nomacopan, PAS-nomacopan, PHP-303) is common for smaller biotech firms to conserve capital and focus on core strategic assets, especially given the high costs and risks associated with clinical development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.
• However, for a pre-clinical stage biotechnology company, incurring substantial losses and requiring continuous capital raises is standard.
• The pivot to the ADC platform, a high-growth area in oncology, is a strategic move seen across the biotech industry to capture market share in innovative cancer treatments.
• The high volatility and risk associated with early-stage drug development, as reflected in the company's going concern warning, are typical for companies in this sector that have not yet commercialized products.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee of Peak Bio CA, Inc. subsidiary filed a claim for less than $0.1 million in discretionary bonuses from 2022; the company denies the claim and intends to defend itself.
• Settlement agreements were signed with two former consultants for wrongful termination claims, requiring a total payment of $0.4 million in monthly installments through November 2025 and continued vesting of restricted stock unit awards.
• A lawsuit filed by Sabby Volatility Warrant Master Fund Ltd. for alleged breach of contract regarding a warrant exercise was settled on May 7, 2025, by issuing 272,450 ADSs (544,900,000 ordinary shares) to Sabby on June 13, 2025.

Related Party Transactions

• The company assumed notes payable to Dr. Hoyoung Huh (Chairman of the Board) from the Peak Bio acquisition: 2021 Notes (totaling $0.9 million) were cancelled and extinguished for an equal amount of ordinary shares and warrants in March 2025.
• A portion of the January 2024 Note ($0.75 million principal) owed to Dr. Huh was cancelled and extinguished ($837,433 principal and accrued interest) for an equal amount of ordinary shares and warrants in connection with the August 2025 Notes Offering.
• The company entered into unsecured convertible promissory notes (May 2024 Notes) totaling $1.0 million with Dr. Ray Prudo (former Chairman) and Dr. Samir Patel (former CEO); $750,000 was repaid in cash, and $250,000 (principal and accrued interest) was converted into ADSs.
• Lease and administrative services expenses of less than $0.1 million were incurred with The Doctors Laboratory, an entity with a common director, for both the three and six months ended June 30, 2025.
• An amount due of less than $0.1 million to an entity in which Dr. Hoyoung Huh is a director is included in accounts payable.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity/warrant issuances and the 20% original issuance discount on new notes. The 'going concern' doubt poses a substantial risk to investment value.
• Employees experienced a 67% reduction-in-force in May 2024 as part of restructuring, indicating job insecurity. Stock-based compensation is a significant part of executive compensation.
• Creditors: Some notes payable have been settled or converted to equity, but new notes with a 20% discount have been issued, indicating higher risk for new lenders.
• Customers/Patients (Future): The strategic focus on the ADC platform (AKTX-101) could lead to new cancer therapies, but this is a long-term prospect with no immediate impact.
• Suppliers/Vendors: The company settled outstanding payables with a vendor, resulting in a gain, which could indicate past payment issues but also a move towards resolving them.

Next Steps

• Continue investing in ADC-related discovery and pre-clinical development activities.
• Seek strategic partners to advance the development of legacy programs (nomacopan and PAS-nomacopan) externally.
• Seek strategic partners to further the development of the PHP-303 program externally.
• Close the August 2025 Notes Offering in two tranches in August and September 2025.
• Begin remediation efforts for material weaknesses in internal control over financial reporting during the third quarter of 2025.

Key Dates

Recommendation

Despite a reduction in net loss and operating expenses, the company explicitly states 'substantial doubt' about its ability to continue as a going concern due to insufficient cash. It relies heavily on continuous, highly dilutive capital raises, including recent notes with a 20% original issuance discount and significant advisory fees. The strategic pivot to ADCs is long-term and highly uncertain, while legacy programs are being divested. Material weaknesses in internal controls further compound the risk. Given the severe liquidity issues, high burn rate relative to cash, and ongoing dilution, the stock presents a very high risk profile, making it an an unfavorable investment.

Keywords

Akari Therapeutics, AKTX, Antibody-Drug Conjugates, ADCs, Oncology, Cancer Therapy, PH1 payload, AKTX-101, Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Capital Raise, Going Concern, Pre-clinical Development, Warrants, Promissory Notes, Corporate Governance, Risk Factors